Literature DB >> 23636907

Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia.

Ana Rosa da Silveira Costa1, Anupama Vasudevan, Ana Krepischi, Carla Rosenberg, Maria de Lourdes L F Chauffaille.   

Abstract

Acute myeloid leukemia (AML) is a group of clonal diseases, resulting from two classes of mutation. Investigation for additional abnormalities associated with a well-recognized subtype, core-binding factor AML (CBF-AML) can provide further understanding and discrimination to this special group of leukemia. In order to better define genetic alterations in CBF-AML and identify possible cooperating lesions, a single-nucleotide polymorphism-array (SNP-array) analysis was performed, combined to KIT mutation screening, in a set of cases. Validation of SNP-array results was done by array comparative genomic hybridization and FISH. Fifteen cases were analyzed. Three cases had microscopic lesions better delineated by arrays. One case had +22 not identified by arrays. Submicroscopic abnormalities were mostly non-recurrent between samples. Of relevance, four regions were more frequently affected: 4q28, 9p11, 16q22.1, and 16q23. One case had an uncovered unbalanced inv(16) due to submicroscopic deletion of 5´MYH11 and 3´CBFB. Telomeric and large copy number neutral loss of heterozygosity (CNN-LOH) regions (>25 Mb), likely representing uniparental disomy, were detected in four out of fifteen cases. Only three cases had mutation on KIT gene, enhancing the role of abnormalities by SNP-array as presumptive cooperating alterations. Molecular karyotyping can add valuable information to metaphase karyotype analysis, emerging as an important tool to uncover and characterize microscopic, submicroscopic genomic alterations, and CNN-LOH events in the search for cooperating lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636907     DOI: 10.1007/s12032-013-0579-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Hematologic malignancies.

Authors:  D G Gilliland
Journal:  Curr Opin Hematol       Date:  2001-07       Impact factor: 3.284

2.  Genetic alterations of the WWOX gene in breast cancer.

Authors:  Seda Ekizoglu; Mahmut Muslumanoglu; Nejat Dalay; Nur Buyru
Journal:  Med Oncol       Date:  2011-10-08       Impact factor: 3.064

3.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Authors:  Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

4.  Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML.

Authors:  Ana Rosa S Costa; Sintia I Belangero; Maria Isabel Melaragno; Maria de Lourdes Chauffaille
Journal:  Med Oncol       Date:  2011-11-25       Impact factor: 3.064

5.  3'CBFbeta deletion associated with inv(16) in acute myeloid leukemia.

Authors:  Johanna Kelly; Nicola J Foot; Eibhlin Conneally; Helen Enright; Mervyn Humphreys; Karen Saunders; Michael J Neat
Journal:  Cancer Genet Cytogenet       Date:  2005-10-15

Review 6.  Common chromosomal fragile sites and cancer: focus on FRA16D.

Authors:  Louise V O'Keefe; Robert I Richards
Journal:  Cancer Lett       Date:  2005-10-20       Impact factor: 8.679

7.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Authors:  R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

8.  Origins and functional impact of copy number variation in the human genome.

Authors:  Donald F Conrad; Dalila Pinto; Richard Redon; Lars Feuk; Omer Gokcumen; Yujun Zhang; Jan Aerts; T Daniel Andrews; Chris Barnes; Peter Campbell; Tomas Fitzgerald; Min Hu; Chun Hwa Ihm; Kati Kristiansson; Daniel G Macarthur; Jeffrey R Macdonald; Ifejinelo Onyiah; Andy Wing Chun Pang; Sam Robson; Kathy Stirrups; Armand Valsesia; Klaudia Walter; John Wei; Chris Tyler-Smith; Nigel P Carter; Charles Lee; Stephen W Scherer; Matthew E Hurles
Journal:  Nature       Date:  2009-10-07       Impact factor: 49.962

Review 9.  Genetics of myeloid leukemias.

Authors:  Louise M Kelly; D Gary Gilliland
Journal:  Annu Rev Genomics Hum Genet       Date:  2002-04-15       Impact factor: 8.929

Review 10.  Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies.

Authors:  Christine O'Keefe; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2010-01-27       Impact factor: 22.113

View more
  4 in total

1.  Identifying the similarities and differences between single nucleotide polymorphism array (SNPa) analysis and karyotyping in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Thiago Rodrigo de Noronha; Sandra Serson Rohr; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2014-11-21

2.  CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.

Authors:  Ting Li; Yingying Cheng; Pingzhang Wang; Wenyan Wang; Fengzhan Hu; Xiaoning Mo; Hongxia Lv; Tao Xu; Wenling Han
Journal:  J Exp Clin Cancer Res       Date:  2015-10-16

3.  Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression.

Authors:  Jun Gu; Keyur P Patel; Bing Bai; Ching-Hua Liu; Guilin Tang; Hagop M Kantarjian; Zhenya Tang; Ronald Abraham; Rajyalakshmi Luthra; L Jeffrey Medeiros; Pei Lin; Xinyan Lu
Journal:  Mol Cytogenet       Date:  2015-08-19       Impact factor: 2.009

Review 4.  Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia.

Authors:  Ilaria Iacobucci; Annalisa Lonetti; Cristina Papayannidis; Giovanni Martinelli
Journal:  Curr Cancer Drug Targets       Date:  2013-09       Impact factor: 3.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.